GTS Securities’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-11,151
Closed -$38K 2071
2024
Q3
$38K Sell
11,151
-6,060
-35% -$26.4K ﹤0.01% 3917
2024
Q2
$80.4K Sell
17,211
-5,100
-23% -$28.8K ﹤0.01% 3655
2024
Q1
$166K Sell
22,311
-28,757
-56% -$239K ﹤0.01% 3405
2023
Q4
$517K Buy
51,068
+23,975
+88% +$210K ﹤0.01% 2762
2023
Q3
$211K Buy
27,093
+14,918
+123% +$128K ﹤0.01% 3368
2023
Q2
$100K Buy
+12,175
New +$106K ﹤0.01% 1100

Other funds holding EDIT

GTS Securities's EDIT Position: Q4 2024 in Review

GTS Securities sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 11,151 shares — an estimated $38K sold.

GTS Securities first reported a position in EDIT in Q2 2023 and held it in 6 quarters. The position peaked at $517K in Q4 2023. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • GTS Securities reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 11,151 Editas Medicine shares in Q4 2024, an estimated $38K.
  • GTS Securities first reported a position in Editas Medicine in Q2 2023 and held it in 6 quarters.
  • GTS Securities's Editas Medicine position peaked at $517K in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.